Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 12/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4424245 | 0.88 | CREBBP (0.61) | CREBBPTRPV1LMNATP53BRD4 | |
| SCHEMBL4434512 | 0.88 | CREBBP (0.73) | CREBBPTRPV1LMNATP53RORC | |
| SCHEMBL4422899 | 0.88 | CREBBP (0.67) | CREBBPTRPV1LMNATP53BRD4 | |
| SCHEMBL4429044 | 0.87 | CREBBP (0.60) | CREBBPTRPV1LMNATP53BRD4 | |
| SCHEMBL4434191 | 0.83 | CREBBP (0.77) | CREBBPTRPV1LMNATP53BRD4 | |
| SCHEMBL4426859 | 0.83 | CREBBP (0.62) | CREBBPTRPV1LMNATP53 | |
| SCHEMBL4427367 | 0.83 | CREBBP (0.56) | CREBBPTRPV1LMNATP53BRD4 | |
| SCHEMBL13998316 | 0.83 | TRPV1 (0.64) | CREBBPTRPV1LMNATP53RORC | |
| SCHEMBL13865652 | 0.82 | CREBBP (0.60) | CREBBPTRPV1LMNATP53BRD4 | |
| SCHEMBL4427395 | 0.82 | TRPV1 (0.59) | CREBBPTRPV1LMNATP53BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |